Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders

Diabetes and Metabolism

Volumn 33, Issue 6, 2007, Pages 395-402

  Viollet, B ^a,b   Mounier, R ^a,b   Leclerc, J ^a,b   Yazigi, A ^b   Foretz, M ^a,b   Andreelli, F ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

Author keywords

AMPK; Energy metabolism; Review; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; ADIPOCYTOKINE; ADIPONECTIN; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN SENSITIZING AGENT; LEPTIN; METFORMIN; PHENFORMIN; PIOGLITAZONE; PROTEIN KINASE; PROTEIN KINASE LKB1; REGULATOR PROTEIN; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ALPHA CHAIN; BETA CHAIN; CELL ENERGY; DISEASE COURSE; DRUG TARGETING; ENERGY BALANCE; ENERGY EXPENDITURE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME REGULATION; ENZYME STRUCTURE; FATTY ACID OXIDATION; FOOD INTAKE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN RELEASE; LIPID METABOLISM; LIPOGENESIS; LIVER; METABOLIC DISORDER; MUSCLE CONTRACTION; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APPETITE; GLUCOSE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; LIPIDS; LIVER; METABOLIC DISEASES; MICE; MICE, KNOCKOUT; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION; PROTEIN-SERINE-THREONINE KINASES;

EID: 36849061190     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2007.10.004     Document Type: Review

References (40)

1. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
2. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
3. Hardie D.G. The AMP-activated protein kinase pathway: new players upstream and downstream. J. Cell Sci. 117 (2004) 5479-5487
4. Viollet B., Andreelli F., Jorgensen S.B., Perrin C., Flamez D., Mu J., et al. Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem. Soc. Trans. 31 Pt 1 (2003) 216-219
5. Wojtaszewski J.F., Birk J.B., Frosig C., Holten M., Pilegaard H., and Dela F. 5'AMP activated protein kinase expression in human skeletal muscle: effects of strength training and type 2 diabetes. J. Physiol. 564 (2005) 563-573
6. Merrill G.F., Kurth E.J., Hardie D.G., and Winder W.W. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol. 273 (1997) E1107-E1112
7. Mu J., Barton E.R., and Birnbaum M.J. Selective suppression of AMP-activated protein kinase in skeletal muscle: update on 'lazy mice'. Biochem. Soc. Trans. 31 (2003) 236-241
8. Suwa M., Egashira T., Nakano H., Sasaki H., and Kumagai S. Metformin increases the PGC-1{alpha} protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J. Appl. Physiol. 101 (2006) 1685-1692
9. Reznick R.M., Zong H., Li J., Morino K., Moore I.K., Yu H.J., et al. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab. 5 (2007) 151-156
10. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., and Diehl A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6 (2000) 998-1003
11. Dagon Y., Avraham Y., and Berry E.M. AMPK activation regulates apoptosis, adipogenesis, and lipolysis by eIF2alpha in adipocytes. Biochem. Biophys. Res. Commun. 340 (2006) 43-47
12. Russell III R.R., Li J., Coven D.L., Pypaert M., Zechner C., Palmeri M., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 114 (2004) 495-503
13. Opie L.H. Effects of regional ischemia on metabolism of glucose and fatty acids. Relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia. Circ. Res. 38 (1976) I52-I74
14. Zarrinpashneh E., Carjaval K., Beauloye C., Ginion A., Mateo P., Pouleur A.C., et al. Role of the alpha2 isoform of AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H2875-H2883
15. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 10 (2005) 1096-1103
16. Shibata R., Ouchi N., Ito M., Kihara S., Shiojima I., Pimentel D.R., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10 (2004) 1384-1389
17. Liao Y., Takashima S., Maeda N., Ouchi N., Komamura K., Shimomura I., et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 67 (2005) 705-713
18. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
19. Sattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A.M., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114 (2006) 623-629
20. Andreelli F., Foretz M., Knauf C., Cani P.D., Perrin C., Iglesias M.A., et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147 (2006) 2432-2441
21. Foretz M., Ancellin N., Andreelli F., Saintillan Y., Grondin P., Kahn A., et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 54 (2005) 1331-1339
22. Bergeron R., Previs S.F., Cline G.W., Perret P., Russell III R.R., Young L.H., et al. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50 (2001) 1076-1082
23. Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., and Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
24. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001) 941-946
25. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002) 1288-1295
26. Cool B., Zinker B., Chiou W., Kifle L., Cao N., Perham M., et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3 (2006) 403-416
27. Carey D.G., Cowin G.J., Galloway G.J., Jones N.P., Richards J.C., Biswas N., et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes. Res. 10 (2002) 1008-1015
28. Simha V., Szczepaniak L.S., Wagner A.J., DePaoli A.M., and Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 26 (2003) 30-35
29. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001) 1167-1174
30. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2006) 1642-1646
31. Satoh H., Nguyen M.T., Miles P.D., Imamura T., Usui I., and Olefsky J.M. Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J. Clin. Invest. 114 (2004) 224-231
32. Viollet B., Andreelli F., Jorgensen S.B., Perrin C., Geloen A., Flamez D., et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Invest. 111 (2003) 91-98
33. Leclerc I., Woltersdorf W.W., da Silva Xavier G., Rowe R.L., Cross S.E., Korbutt G.S., et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am. J. Physiol. Endocrinol. Metab. 286 (2004) E1023-E1031
34. Richards S.K., Parton L.E., Leclerc I., Rutter G.A., and Smith R.M. Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J. Endocrinol. 187 (2005) 225-235
35. Minokoshi Y., Alquier T., Furukawa N., Kim Y.B., Lee A., Xue B., et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428 (2004) 569-574
36. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005) 1642-1646
37. Brunmair B., Staniek K., Gras F., Scharf N., Althaym A., Clara R., et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 53 (2004) 1052-1059
38. Saha A.K., Avilucea P.R., Ye J.M., Assifi M.M., Kraegen E.W., and Ruderman N.B. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem. Biophys. Res. Commun. 314 (2004) 580-585
39. Nawrocki A.R., Rajala M.W., Tomas E., Pajvani U.B., Saha A.K., Trumbauer M.E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 281 (2006) 2654-2660
40. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51 (2002) 2074-2081